<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>pediatric patients &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/pediatric-patients/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 16 Nov 2025 01:00:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>pediatric patients &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Myocardium Suppression After Remdesivir in Congenital Heart Patients</title>
		<link>https://bioengineer.org/myocardium-suppression-after-remdesivir-in-congenital-heart-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 16 Nov 2025 00:59:42 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antiviral Treatment Complications` **Seçimlerin kısa açıklaması:** 1. **Remdesivir:** Makalenin ve vakaların merkezindeki ilaç. 2. **Congenital Heart Disease:** Etkilenen]]></category>
		<category><![CDATA[congenital heart disease]]></category>
		<category><![CDATA[İşte 5 uygun etiket]]></category>
		<category><![CDATA[Myocardium Suppression]]></category>
		<category><![CDATA[pediatric patients]]></category>
		<category><![CDATA[virgülle ayrılmış halde: `Remdesivir]]></category>
		<guid isPermaLink="false">https://bioengineer.org/myocardium-suppression-after-remdesivir-in-congenital-heart-patients/</guid>

					<description><![CDATA[In a groundbreaking case report, a team of researchers has documented the rare occurrence of severe myocardium suppression in two pediatric patients with congenital heart disease following the administration of remdesivir. This antiviral drug, initially developed for the treatment of viral infections such as Ebola and later repurposed for COVID-19, has now attracted attention due [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">297442</post-id>	</item>
		<item>
		<title>Healthcare Costs of ADHD-Related Adverse Events</title>
		<link>https://bioengineer.org/healthcare-costs-of-adhd-related-adverse-events/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Sep 2025 11:58:44 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[ADHD adverse events]]></category>
		<category><![CDATA[claims-based study]]></category>
		<category><![CDATA[healthcare costs]]></category>
		<category><![CDATA[healthcare system burden]]></category>
		<category><![CDATA[pediatric patients]]></category>
		<guid isPermaLink="false">https://bioengineer.org/healthcare-costs-of-adhd-related-adverse-events/</guid>

					<description><![CDATA[In a groundbreaking study published in Advances in Therapy, researchers led by Schein et al. reveal the staggering healthcare costs associated with adverse events in pediatric patients diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). The study, leveraging extensive claims data, highlights a critical and often overlooked aspect of ADHD management — the economic burden that adverse events [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268689</post-id>	</item>
	</channel>
</rss>
